Professor David Holt
Professor Holt holds the Chair of Bioanalytics at St George's Hospital Medical School, London, England, where he is the Director of the Analytical Unit in the Department of Cardiac and Vascular Sciences. The laboratory is an accredited GLP facility which has provided bioanalytical services to major Pharmas in support of numerous international clinical studies. A wide range of analytical techniques are available within the laboratory, including high-performance liquid chromatography with tandem mass-spectrometric detection (HPLC/MS/MS). Professor Holt is a clinical biochemist with more than 34 years' experience in the measurement of drugs as a guide to therapy and he has been responsible for the development of assays used to monitor a wide variety of therapeutic agents. He has been involved in definitive clinical pharmacokinetic studies of antiarrhythmic and immunosuppressive drugs and is the organiser of International Proficiency Testing Schemes for immunosuppressive drugs. He is also responsible for Forensic Toxicology Services at St George's Hospital Medical School. Professor Holt has advised on several consensus panels on immunosuppressive drug monitoring and is the chairman of the International Federation of Clinical Chemistry Working Group on immunosuppressive drug monitoring. His current research interests include the development of mass-spectrometric assays for the measurement of endogenous markers of organ damage and dysfunction, pharmacogenetics of immunosuppressive drugs, the development of methods to assess phenotypic markers of drug metabolism and the detection of drugs used in drug-assisted sexual assault. He is a frequent speaker on a broad range of issues relating to analytical clinical toxicology and is the author of over 300 publications in peer reviewed journals and invited contributions to books. He is President-elect of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Some of Professor Holt’s most important peer-reviewed publications include:
- Amiodarone: side effects of long-term therapy. Circulation 1983;67:45–51
- Amiodarone pharmacokinetics. American Heart Journal 1983; 106:840–7.
- Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985;72:1064–75.
- Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. Clinical Chemistry 1988;34:1091–6.
- Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. British Heart Journal 1989;62:133–9.
- Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clinical Chemistry 1990;36:1510–6.
- Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage. Clinical Chemistry 1994;40:1265–71.
- Monitoring new immunosuppressive agents. Are the methods adequate? Drug Metabolism & Drug Interactions 1997;14:5–15.
- Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clinical Chemistry 2000;46:1179–83.
- Cardiac troponin T and CK-MB content of skeletal muscle is not increased in patients with renal failure. Clinical Chemistry 2001;47(6):1023–30.
- Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74(11):1486–9.
- The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004;4:914–9
- Pregnancy associated plasma protein A (PAPP-A) and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP) are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004;109:1724–8
